MY202118A - Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus - Google Patents

Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Info

Publication number
MY202118A
MY202118A MYPI2018703588A MYPI2018703588A MY202118A MY 202118 A MY202118 A MY 202118A MY PI2018703588 A MYPI2018703588 A MY PI2018703588A MY PI2018703588 A MYPI2018703588 A MY PI2018703588A MY 202118 A MY202118 A MY 202118A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
virus
hepatitis
antigen
antigens
Prior art date
Application number
MYPI2018703588A
Other languages
English (en)
Inventor
Csar AGUILAR RUBIDO Julio
Lobaina Mato Yadira
Iglesias Perez Enrique
Pentn Arias Eduardo
Enrique Guilln Nieto Gerardo
Agustn Aguiar Santiago Jorge
Gonzalez Blanco Sonia
Valdes Hernandez Jorge
Vazquez Castillo Mariela
Original Assignee
Centro De Ingeniera Gentica Y Biotecnologa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingeniera Gentica Y Biotecnologa filed Critical Centro De Ingeniera Gentica Y Biotecnologa
Publication of MY202118A publication Critical patent/MY202118A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2018703588A 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus MY202118A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
MY202118A true MY202118A (en) 2024-04-04

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018703588A MY202118A (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Country Status (18)

Country Link
US (2) US11491218B2 (enExample)
EP (1) EP3437654B1 (enExample)
JP (1) JP6981992B2 (enExample)
KR (1) KR20180125985A (enExample)
CN (1) CN109219449B (enExample)
AR (1) AR108009A1 (enExample)
AU (1) AU2017243136B2 (enExample)
BR (1) BR112018069738A2 (enExample)
CA (1) CA3017778A1 (enExample)
CU (1) CU24454B1 (enExample)
EA (1) EA201892212A1 (enExample)
ES (1) ES2965709T3 (enExample)
MX (1) MX2018011793A (enExample)
MY (1) MY202118A (enExample)
TW (1) TWI755383B (enExample)
UA (1) UA128952C2 (enExample)
WO (1) WO2017167317A1 (enExample)
ZA (1) ZA201806325B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020355020A1 (en) * 2019-09-23 2022-04-28 Ascendo Biotechnology, Inc. Biodegradable nanocomplex vaccines, methods for suppression of hepapitis B virus replication and hepapitis B virus surface antigen secretion
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN110859961A (zh) * 2013-07-26 2020-03-06 复旦大学 病毒免疫治疗药物复合物在制备治疗hbv感染药物中的应用

Also Published As

Publication number Publication date
EP3437654B1 (en) 2023-09-20
ZA201806325B (en) 2020-08-26
EA201892212A1 (ru) 2019-03-29
HK1259329A1 (zh) 2019-11-29
CU20160038A7 (es) 2017-11-07
JP2019510064A (ja) 2019-04-11
ES2965709T3 (es) 2024-04-16
CN109219449B (zh) 2022-08-30
AR108009A1 (es) 2018-07-04
AU2017243136B2 (en) 2022-02-17
CU24454B1 (es) 2019-11-04
UA128952C2 (uk) 2024-12-11
WO2017167317A1 (es) 2017-10-05
US20220193228A1 (en) 2022-06-23
EP3437654A1 (en) 2019-02-06
US20200297840A1 (en) 2020-09-24
TWI755383B (zh) 2022-02-21
US11491218B2 (en) 2022-11-08
CN109219449A (zh) 2019-01-15
KR20180125985A (ko) 2018-11-26
CA3017778A1 (en) 2017-10-05
US11759517B2 (en) 2023-09-19
JP6981992B2 (ja) 2021-12-17
AU2017243136A1 (en) 2018-10-11
TW201735945A (zh) 2017-10-16
MX2018011793A (es) 2018-12-17
BR112018069738A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
PH12019500245A1 (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
PH12019550220A1 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表达沉默的组合物及方法
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
JP2015096557A5 (enExample)
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
WO2016183366A3 (en) Compositions and methods for silencing expression of hepatitis d virus rna
EA201500114A1 (ru) Композиция антитела для предупреждения или лечения инфекции мутантным вирусом гепатита b
MY202118A (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
ZA202001413B (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
JP2019510064A5 (enExample)
CN104059916A (zh) 乙肝病毒特异性的microRNA样siRNA序列及其用途
WO2020254878A8 (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b.
HK40074665A (en) Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
GR1008805B (el) Στερεο φαρμακευτικο σκευασμα περιεχον χαμηλη δοση εντεκαβιρης και μεθοδος παρασκευης αυτου
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B
CN104059917A (zh) 乙肝病毒特异性的microRNA样siRNA序列及其用途
PL410950A1 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV
MX2013009310A (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.